Health and Healthcare
Cathie Wood's ARK Invest Buys Over 1 Million Shares of Iovance Bio
Published:
A couple of the ARK exchange-traded funds run by ETF star Cathie Wood made huge purchases on Thursday. These funds bought over 1 million shares of Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares on Thursday, as the price of these ETFs rose around 3% on Thursday. Note that these ETFs are still up handily in the last year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 201,664 shares, while ARK Innovation ETF (NYSEARCA: ARKK) bought 808,642 shares of Iovance. At Thursday’s closing price this would have valued this purchase at $18.9 million. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 65%, and ARKK is up 75% in the last year.
Check out all of ARK Invest’s buys for Thursday:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | COIN | COINBASE GLOBAL INC | 38,220 |
| ARKF | KSPILI | KASPI.KZ JSC | 4,436 |
| ARKG | RXRX | RECURSION PHARMACEUTICALS INC | 14,440 |
| ARKG | ONEM | 1LIFE HEALTHCARE INC | 144,563 |
| ARKG | SGFY | SIGNIFY HEALTH INC | 139,900 |
| ARKG | IOVA | IOVANCE BIOTHERAPEUTICS INC | 201,664 |
| ARKG | CSTL | CASTLE BIOSCIENCES INC | 11,536 |
| ARKG | CMIIU | CM LIFE SCIENCES II INC | 305 |
| ARKG | CDXS | CODEXIS INC | 1,929 |
| ARKG | MASS | 908 DEVICES INC | 13,080 |
| ARKG | RPTX | REPARE THERAPEUTICS INC | 41,780 |
| ARKK | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA INC | 7,496 |
| ARKK | IOVA | IOVANCE BIOTHERAPEUTICS INC | 808,642 |
| ARKK | EXAS | EXACT SCIENCES CORP | 125,929 |
| ARKK | COIN | COINBASE GLOBAL INC | 216,518 |
| ARKK | BEAM | BEAM THERAPEUTICS INC | 30,000 |
| ARKQ | ACIC | ATLAS CREST INVESTMENT CORP | 421,940 |
| ARKQ | PATH | UIPATH INC | 6,131 |
| ARKQ | NIU | NIU TECHNOLOGIES | 125,271 |
| ARKX | BLDE | BLADE AIR MOBILITY INC | 105,037 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of a673b.bigscoots-temp.com.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
